MedExecWomen Third Annual Conference in Boston, June 14, 2022

Empowering Women in Leadership Roles in the Medical Device, Diagnostics, and Digital Health Industries BOSTON–(BUSINESS WIRE)–MedExecWomen, a fast-growing organization dedicated to empowering women in leadership roles in medical device, diagnostics, drug delivery, and digital healthcare, announced today their third annual event will take place on June 14, 2022, in Boston. Attendance is limited to 150 … [Read more…]

Illumina Ventures Announces Promotion and Additions to its Investment Team

Malek Faham promoted to Chief Scientist FOSTER CITY, Calif.–(BUSINESS WIRE)–Illumina Ventures, today announced the promotion of Malek Faham, MD, PhD, to Chief Scientist having previously served as both a Venture Partner and Entrepreneur in Residence (EIR). In addition, Charles Lin, PhD, has joined the team as a Principal, and Dave Johnson, PhD, has joined as … [Read more…]

Amneal to Participate at the 2022 Jefferies Healthcare Conference

BRIDGEWATER, N.J.–(BUSINESS WIRE)–Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the “Company”) today announced that Chirag Patel, Co-Chief Executive Officer and President, and Tasos Konidaris, Chief Financial Officer, will participate at the 2022 Jefferies Healthcare Conference held on June 8, 2022 in New York City. Mr. Patel will also be hosting a presentation which will begin at 8:00 … [Read more…]

LUXA BIO Announces First Participant Dosed in Phase 1/2a Clinical Trial of Adult RPESC-RPE-4W for Dry Age-related Macular Degeneration

FORT LEE, N.J.–(BUSINESS WIRE)–Luxa Biotechnology (LuxaBio), a joint venture between Y2 Solution Co. Ltd, Seoul, South Korea and the Neural Stem Cell Institute (NSCI), Rensselaer, New York, today announced transplantation of the cell product RPESC-RPE-4W into the first participant with dry age-related macular degeneration (dry AMD) in its Phase 1/2a clinical trial (NCT04627428) being conducted … [Read more…]

Drips Announces Executive Promotions

Conversational AI Pioneer Announces Executive Promotions Due to Continued Growth AKRON, Ohio–(BUSINESS WIRE)–Drips is pleased to announce the recent promotion of two of its top-level executives. In the past 12 months, Drips made tremendous strides in capturing market opportunities in key verticals such as healthcare, insurance, and financial services. The Drips team grew from 90 … [Read more…]

Aldeyra Therapeutics Designates Schirmer Test as Sole Primary Endpoint in Phase 3 TRANQUILITY-2 Trial of Reproxalap in Dry Eye Disease

Selection Follows Post-Hoc Analysis Demonstrating Statistical Significance of Reproxalap Over Vehicle in Ocular Redness in Completed TRANQUILITY Trial LEXINGTON, Mass.–(BUSINESS WIRE)–Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced the designation of Schirmer test, a measure of tear production, as the sole primary endpoint in the Phase 3 TRANQUILITY-2 clinical trial of reproxalap in patients with … [Read more…]

Cosette Pharmaceuticals and Alembic Pharmaceuticals Limited Announce the Approval and Launch of a National Brand Equivalent (NBE) of Abreva® (Docosanol Cream 10%) Including the First Approval in the Pump Format

BRIDGEWATER, N.J. & VADODARA, India–(BUSINESS WIRE)–#abreva–Cosette Pharmaceuticals, Inc (“Cosette”), in collaboration with Aleor Dermaceuticals, a wholly owned subsidiary of Alembic Pharmaceuticals (“Alembic”; BSE: 533573), announced that the U.S. Food and Drug Administration (FDA) has approved the Abbreviated New Drug Application (ANDA) for an NBE version of Abreva® (Docosanol cream 10%) in a 2 gm tube … [Read more…]

Alnylam Presents New Results from the ILLUMINATE-C Phase 3 Study of Lumasiran in Patients with Advanced Primary Hyperoxaluria Type 1

– Lumasiran Demonstrated Evidence of Improvements in Exploratory Endpoints of Systemic Oxalosis, Including Echocardiographic Structure and Function, Nephrocalcinosis, and Kidney Stone Events – – Expands Upon Previously Reported Reductions in Plasma Oxalate in PH1 Patients with Severe Renal Impairment – CAMBRIDGE, Mass.–(BUSINESS WIRE)–Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new … [Read more…]

Alvotech Clinical Study Results Demonstrate Therapeutic Equivalence between Biosimilar Candidate AVT04 and Reference Product Stelara®

The confirmatory clinical, safety and efficacy study for AVT04, biosimilar candidate to Stelara® (ustekinumab) met its primary endpoint AVT04 (ustekinumab) is part of a broader pipeline of Alvotech’s biosimilars and biosimilar candidates, which includes AVT02 (adalimumab), a biosimilar to Humira® Alvotech is the second company to announce positive top-line results from a patient study utilizing … [Read more…]

Edgility, Inc. Launches EdgeAi, a Breakthrough Explainable and Open-Box Artificial Intelligence to Accelerate Adoption

TAMPA, Fla.–(BUSINESS WIRE)–Edgility, Inc. launches EdgeAi as healthcare’s first operationally embedded AI with Explainability. EdgeAi exposes the internal mechanics of machine learning and deep learning systems in human-understandable terms. Trust in AI model predictions is paramount if care providers and administrators are to accept the decisions based on them. EdgeAi generates a standard label for … [Read more…]